Related references
Note: Only part of the references are listed.
Article
Neurosciences
Friederike Holze et al.
Summary: This study investigated the efficacy and safety of LSD-assisted therapy in patients with anxiety, with or without a life-threatening illness. The results showed that LSD treatment led to significant reductions in anxiety and comorbid depression symptoms, with effects lasting up to 16 weeks.
BIOLOGICAL PSYCHIATRY
(2023)
Editorial Material
Medicine, General & Internal
Matt Lamkin
AMERICAN JOURNAL OF MEDICINE
(2022)
Article
Biotechnology & Applied Microbiology
Tristan D. McClure-Begley et al.
Summary: Psychedelic drugs have emerging therapeutic potential for neuropsychiatric diseases, but there are still many challenges and uncertainties. Further research is needed to understand the mechanisms of action and develop cleaner drugs to fully realize their therapeutic potential.
NATURE REVIEWS DRUG DISCOVERY
(2022)
Article
Neurosciences
Steven F. Grieco et al.
Summary: Psychedelic drugs have regained attention as tools for treating brain disorders. Recent research suggests that they may exert therapeutic effects by influencing neural plasticity. This article showcases basic and clinical research on the mechanisms of psychedelic drugs, covering topics such as receptor binding, gene expression, and their effects on brain circuits.
JOURNAL OF NEUROSCIENCE
(2022)
Review
Clinical Neurology
Joost J. Breeksema et al.
Summary: The use of psychedelic drugs for the treatment of mental disorders has shown promising results. However, the adverse events associated with psychedelic treatments are poorly defined and often underreported in the literature due to study design and sample selection limitations.
JOURNAL OF PSYCHOPHARMACOLOGY
(2022)
Editorial Material
Medicine, General & Internal
Bertha K. Madras
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Guy M. Goodwin et al.
Summary: Psilocybin may be effective in treating treatment-resistant depression, but dosage and adverse effects need further investigation.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Neurosciences
Matt Butler et al.
Summary: This article discusses the role of blinding and expectancy in psychedelic trials, and places it in the context of trials in healthcare. The premature and uncritical promotion of psychedelics as medicines is misleading and influences participant expectancy in ongoing trials. While psychedelic trials may overestimate treatment effects due to unblinding and expectancy effects, placebo-controlled RCTs are not perfect for all therapeutics. Practical measures such as independent raters and active placebos can mitigate the effects, and alternative trial methodologies like naturalistic studies can be considered to bolster RCT results.
PSYCHOPHARMACOLOGY
(2022)
Article
Psychiatry
Michael P. Bogenschutz et al.
Summary: This study aimed to evaluate the effects of high-dose psilocybin on patients with AUD. The results showed that psilocybin combined with psychotherapy significantly decreased the percentage of heavy drinking days.
Review
Psychology, Clinical
David M. Horton et al.
Summary: This systematic review focused on investigating the structure and format of psilocybin-assisted psychotherapy (PAP), highlighting the counseling components of the treatment. The study identified commonalities in PAP clinical trials published within the past 25 years, while also noting key differences in the incorporation of psychotherapy. Further research is needed to understand the unique effects of psychotherapy in PAP.
AMERICAN JOURNAL OF PSYCHOTHERAPY
(2021)
Review
Pharmacology & Pharmacy
Sandeep Nayak et al.
Summary: This article explores the similarities and differences between psychedelic therapy and conventional psychotherapy, as well as the potential for psychedelic drug effects to enhance conventional therapeutic processes. By considering shared features of conventional psychotherapies and unique psychedelic drug effects, the article aims to provide a framework for understanding the effectiveness of psychedelics in diverse types of psychotherapies. Additionally, it reviews the inclusion of formal psychotherapies in modern psychedelic trials and discusses implications for clinical ethics and trial design.
PHARMACOPSYCHIATRY
(2021)
Article
Multidisciplinary Sciences
Paul Tullis
Article
Pharmacology & Pharmacy
Sandeep M. Nayak et al.
Summary: The combination of classic psychedelics with mood stabilizers, particularly lithium, may significantly increase the risk of seizures, as indicated by reports analyzed from online forums. Further research is needed to fully understand the potential risks and interactions.
PHARMACOPSYCHIATRY
(2021)
Article
Multidisciplinary Sciences
Patrick Vizeli et al.
Summary: The study explored the impact of genetic polymorphisms of CYP genes on the pharmacokinetics and acute effects of LSD in healthy subjects. It found that CYP2D6 functionality significantly influenced the pharmacokinetics of LSD and subjective effects experienced by individuals.
SCIENTIFIC REPORTS
(2021)
Review
Pharmacology & Pharmacy
Suresh D. Muthukumaraswamy et al.
Summary: This study reviewed previous literature on expectancy effects and blinding in psychedelic RCTs and found that these trials might be influenced by de-blinding and expectancy. Current psychedelic RCTs generally do not report pre-trial expectancy or the success rate of blinding procedures. The authors suggest caution in interpreting effect size estimates from existing psychedelic RCTs due to potential confounds related to de-blinding and expectancy.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
(2021)
Article
Clinical Neurology
Gabrielle Agin-Liebes et al.
JOURNAL OF PSYCHOPHARMACOLOGY
(2020)
Article
Clinical Neurology
Robin L. Carhart-Harris et al.
JOURNAL OF PSYCHOPHARMACOLOGY
(2018)
Article
Psychology, Clinical
Matthew W. Johnson et al.
AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE
(2017)
Article
Clinical Neurology
Frederick S. Barrett et al.
JOURNAL OF PSYCHOPHARMACOLOGY
(2016)
Review
Clinical Neurology
M. W. Johnson et al.
JOURNAL OF PSYCHOPHARMACOLOGY
(2008)
